The Inflation Reduction Act and Access to High-Cost Cardiovascular Therapies-Reference-Cited by-同舟云学术

The Inflation Reduction Act and Access to High-Cost Cardiovascular Therapies

Published:2023-11-07 Issue:17 Volume:330 Page:1619
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Kazi Dhruv S.¹²,Wadhera Rishi K.¹²,Rome Benjamin N.²³

Affiliation:

1. Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts

2. Harvard Medical School, Boston, Massachusetts

3. Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts

Abstract

This Viewpoint discusses how the price negotiation for certain drugs under the Inflation Reduction Act will provide a unique opportunity to enhance access to therapies for older patients with cardiovascular conditions and diabetes.

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2809885/jama_kazi_2023_vp_230127_1698789062.70973.pdf

Reference7 articles.

1. National trends in use of and spending on oral anticoagulants among US Medicare beneficiaries from 2011 to 2019.;Troy;JAMA Health Forum,2021

2. The Inflation Reduction Act and out-of-pocket drug costs for Medicare beneficiaries with cardiovascular disease.;Kazi;J Am Coll Cardiol,2023

3. Free speech challenges to the Inflation Reduction Act.;Tu;JAMA

4. Out-of-pocket drug costs for Medicare beneficiaries with cardiovascular risk factors under the Inflation Reduction Act.;Narasimmaraj;J Am Coll Cardiol,2023

5. HHS selects the first drugs for Medicare drug price negotiation. August 29, 2023. Accessed August 29, 2023. https://www.hhs.gov/about/news/2023/08/29/hhs-selects-the-first-drugs-for-medicare-drug-price-negotiation.html

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of competition on reimbursement decisions for cancer drugs in China: an observational study;The Lancet Regional Health - Western Pacific;2024-09

2. Forecasting the Economic Burden of Cardiovascular Disease and Stroke in the United States Through 2050: A Presidential Advisory From the American Heart Association;Circulation;2024-07-23

3. The Inflation Reduction Act and Access to Heart Failure Therapies: Prices, Progress and Promise;Journal of Cardiac Failure;2024-05

4. Novel cardiovascular therapeutics and the risk of financial toxicity;Nature Reviews Cardiology;2024-03-14

5. Ethical Complexity of Medical Treatment Affordability and Clinical Trial Diversity in Heart Failure;Circulation: Cardiovascular Quality and Outcomes;2024-02